Peel Hunt Reiterates “Hold” Rating for BTG (BTG)
BTG (LON:BTG)‘s stock had its “hold” rating reissued by Peel Hunt in a research note issued on Tuesday.
Several other research analysts have also commented on BTG. JPMorgan Chase dropped their price objective on shares of BTG from GBX 750 ($10.17) to GBX 680 ($9.22) and set a “neutral” rating for the company in a research note on Friday, April 6th. Numis Securities reaffirmed a “buy” rating and set a GBX 900 ($12.21) price objective on shares of BTG in a research note on Wednesday, January 24th. Finally, Shore Capital raised shares of BTG to a “buy” rating in a research note on Monday, March 26th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. BTG currently has a consensus rating of “Buy” and an average price target of GBX 779.71 ($10.58).
Shares of BTG opened at GBX 632.95 ($8.59) on Tuesday. BTG has a fifty-two week low of GBX 559.82 ($7.59) and a fifty-two week high of GBX 784 ($10.63).
BTG Company Profile
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.